Aditxt (ADTX) Competitors $5.00 -1.16 (-18.83%) Closing price 04:00 PM EasternExtended Trading$4.99 -0.01 (-0.20%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ADTX vs. KTTA, PBLA, ONCT, VCNX, PCSA, ERNA, BPTH, MBIO, WINT, and GLMDShould you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Pasithea Therapeutics (KTTA), Panbela Therapeutics (PBLA), Oncternal Therapeutics (ONCT), Vaccinex (VCNX), Processa Pharmaceuticals (PCSA), Eterna Therapeutics (ERNA), Bio-Path (BPTH), Mustang Bio (MBIO), Windtree Therapeutics (WINT), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry. Aditxt vs. Pasithea Therapeutics Panbela Therapeutics Oncternal Therapeutics Vaccinex Processa Pharmaceuticals Eterna Therapeutics Bio-Path Mustang Bio Windtree Therapeutics Galmed Pharmaceuticals Aditxt (NASDAQ:ADTX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Does the MarketBeat Community believe in ADTX or KTTA? Aditxt received 2 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 44.44% of users gave Aditxt an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformAditxtOutperform Votes444.44% Underperform Votes555.56% Pasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Does the media favor ADTX or KTTA? In the previous week, Aditxt had 4 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 7 mentions for Aditxt and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.08 beat Aditxt's score of 0.34 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aditxt 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ADTX or KTTA? Pasithea Therapeutics has lower revenue, but higher earnings than Aditxt. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAditxt$212.11K1.34-$32.38MN/AN/APasithea TherapeuticsN/AN/A-$15.96M-$12.69-0.11 Which has more volatility and risk, ADTX or KTTA? Aditxt has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Is ADTX or KTTA more profitable? Pasithea Therapeutics' return on equity of -81.57% beat Aditxt's return on equity.Company Net Margins Return on Equity Return on Assets AditxtN/A -439.07% -122.96% Pasithea Therapeutics N/A -81.57%-74.31% Do institutionals and insiders hold more shares of ADTX or KTTA? 15.5% of Aditxt shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryPasithea Therapeutics beats Aditxt on 6 of the 11 factors compared between the two stocks. Remove Ads Get Aditxt News Delivered to You Automatically Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADTX vs. The Competition Export to ExcelMetricAditxtPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$285,000.00$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E RatioN/A7.1723.3318.67Price / Sales1.34220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.006.396.894.23Net Income-$32.38M$142.12M$3.20B$247.15M7 Day Performance-48.08%-5.18%-3.02%-2.17%1 Month Performance-67.59%-7.49%1.63%-5.68%1 Year Performance-99.99%-8.78%9.74%-0.67% Aditxt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADTXAditxt0.9747 of 5 stars$5.00-18.8%N/A-100.0%$285,000.00$212,107.000.0060Short Interest ↓Gap DownKTTAPasithea Therapeutics1.3331 of 5 stars$1.25+0.8%N/A-81.5%$1.58MN/A0.003Earnings ReportPBLAPanbela TherapeuticsN/A$0.32-3.0%N/A-51.6%$1.57MN/A0.006Gap UpONCTOncternal Therapeutics1.4645 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530Analyst ForecastNews CoverageVCNXVaccinexN/A$0.58+1.7%N/A-91.9%$1.51M$388,000.00-0.0140Upcoming EarningsNegative NewsGap UpPCSAProcessa Pharmaceuticals4.1248 of 5 stars$0.44+2.0%$6.00+1,268.3%-82.8%$1.43MN/A-0.1320Short Interest ↓News CoveragePositive NewsGap UpERNAEterna Therapeutics1.0035 of 5 stars$0.26-1.7%N/A-90.4%$1.41M$582,000.00-0.0310News CoverageBPTHBio-Path1.6676 of 5 stars$0.16+5.4%$20.00+12,110.0%-95.8%$1.36MN/A0.0010Analyst ForecastNews CoverageGap UpMBIOMustang Bio2.8299 of 5 stars$1.41+0.7%$100.00+6,992.2%-97.1%$1.35MN/A-0.02100Short Interest ↓Gap UpWINTWindtree Therapeutics2.5133 of 5 stars$1.76+18.9%$350.00+19,786.4%-99.5%$1.32MN/A-0.1130Short Interest ↓Gap UpHigh Trading VolumeGLMDGalmed Pharmaceuticals1.2894 of 5 stars$2.03-10.2%N/A-58.7%$1.31MN/A-0.1220Upcoming EarningsAnalyst ForecastShort Interest ↑Gap DownTrading Halted Remove Ads Related Companies and Tools Related Companies Pasithea Therapeutics Alternatives Panbela Therapeutics Alternatives Oncternal Therapeutics Alternatives Vaccinex Alternatives Processa Pharmaceuticals Alternatives Eterna Therapeutics Alternatives Bio-Path Alternatives Mustang Bio Alternatives Windtree Therapeutics Alternatives Galmed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech fir...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADTX Stock Free ADTX Stock Alerts